ITMI960311A0 - - Google Patents

Info

Publication number
ITMI960311A0
ITMI960311A0 ITMI960311A ITMI960311A ITMI960311A0 IT MI960311 A0 ITMI960311 A0 IT MI960311A0 IT MI960311 A ITMI960311 A IT MI960311A IT MI960311 A ITMI960311 A IT MI960311A IT MI960311 A0 ITMI960311 A0 IT MI960311A0
Authority
IT
Italy
Application number
ITMI960311A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ITMI960311A0 publication Critical patent/ITMI960311A0/it
Priority to IT96MI000311A priority Critical patent/IT1282650B1/it
Priority to US08/799,313 priority patent/US5780057A/en
Priority to AT03078109T priority patent/ATE530173T1/de
Priority to ES97102567T priority patent/ES2219709T3/es
Priority to EP03078109A priority patent/EP1382331B1/en
Priority to EP97102567A priority patent/EP0795324B1/en
Priority to ES03078109T priority patent/ES2376199T3/es
Priority to NZ314265A priority patent/NZ314265A/en
Priority to DE69728710T priority patent/DE69728710T2/de
Priority to AT97102567T priority patent/ATE264670T1/de
Priority to DK97102567T priority patent/DK0795324T3/da
Priority to PT97102567T priority patent/PT795324E/pt
Priority to AU14776/97A priority patent/AU719170B2/en
Priority to JP03491897A priority patent/JP3251190B2/ja
Priority to CA002197941A priority patent/CA2197941C/en
Publication of ITMI960311A1 publication Critical patent/ITMI960311A1/it
Application granted granted Critical
Publication of IT1282650B1 publication Critical patent/IT1282650B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
IT96MI000311A 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici IT1282650B1 (it)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US08/799,313 US5780057A (en) 1996-02-19 1997-02-14 Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
DE69728710T DE69728710T2 (de) 1996-02-19 1997-02-18 Eine pharmazeutische Tablette charakterisiert durch hohen Volumenzuwachs bei Kontakt mit biologischen Flüssigkeiten
AT97102567T ATE264670T1 (de) 1996-02-19 1997-02-18 Eine pharmazeutische tablette charakterisiert durch hohen volumenzuwachs bei kontakt mit biologischen flüssigkeiten
EP03078109A EP1382331B1 (en) 1996-02-19 1997-02-18 A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids
EP97102567A EP0795324B1 (en) 1996-02-19 1997-02-18 A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids
ES03078109T ES2376199T3 (es) 1996-02-19 1997-02-18 Un comprimido farmacéutico caracterizado por mostrar un incremento de volumen cuando entra en contacto con fluidos biológicos.
NZ314265A NZ314265A (en) 1996-02-19 1997-02-18 Multilayered compressed tablet for selective release of medicaments at controlled rates having one layer that increases at least 50% by volume on contact with gastric juices
AT03078109T ATE530173T1 (de) 1996-02-19 1997-02-18 Eine pharmazeutische tablette charakterisiert durch hohen volumenzuwachs bei kontakt mit biologischen flüssigkeiten
ES97102567T ES2219709T3 (es) 1996-02-19 1997-02-18 Un comprimido farmaceutico caracterizado porque presenta un gran aumento de volumen cuando entra en contacto con fluidos biologicos.
DK97102567T DK0795324T3 (da) 1996-02-19 1997-02-18 En farmaceutisk tablet kendetegnet ved, at den udviser stor volumenforögelse, når den kommer i kontakt med biologiske væsker
PT97102567T PT795324E (pt) 1996-02-19 1997-02-18 Comprimido farmaceutico caracterizado por apresentar um elevado aumento volumerico quando colocado em contacto com fluidos biologicos
AU14776/97A AU719170B2 (en) 1996-02-19 1997-02-18 Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
JP03491897A JP3251190B2 (ja) 1996-02-19 1997-02-19 体液と接触することにより容積が高度に増加する薬学的圧縮錠剤
CA002197941A CA2197941C (en) 1996-02-19 1997-02-19 A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici

Publications (3)

Publication Number Publication Date
ITMI960311A0 true ITMI960311A0 (it) 1996-02-19
ITMI960311A1 ITMI960311A1 (it) 1997-08-19
IT1282650B1 IT1282650B1 (it) 1998-03-31

Family

ID=11373320

Family Applications (1)

Application Number Title Priority Date Filing Date
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici

Country Status (12)

Country Link
US (1) US5780057A (it)
EP (2) EP1382331B1 (it)
JP (1) JP3251190B2 (it)
AT (2) ATE530173T1 (it)
AU (1) AU719170B2 (it)
CA (1) CA2197941C (it)
DE (1) DE69728710T2 (it)
DK (1) DK0795324T3 (it)
ES (2) ES2219709T3 (it)
IT (1) IT1282650B1 (it)
NZ (1) NZ314265A (it)
PT (1) PT795324E (it)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US5804165A (en) * 1996-07-24 1998-09-08 Arnold; Michael J. Antiplaque oral composition
DE19640062B4 (de) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
IN186245B (it) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
IL136549A (en) * 1997-12-22 2005-05-17 Schering Corp Orally administrable solid ribavirin dosage forms and process for making them
IL139590A0 (en) * 1998-06-05 2002-02-10 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
IL141339A0 (en) * 1998-09-25 2002-03-10 Delsys Pharmaceutical Corp Liquid pharmaceutical for oral delivery
ATE424810T1 (de) 1998-12-11 2009-03-15 Nostrum Pharmaceuticals Inc Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
MY121470A (en) * 1999-05-03 2006-01-28 Ranbaxy Lab Ltd Stable solid pharmaceutical compositions containing enalapril maleate
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
FR2797185B1 (fr) * 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
JP4565456B2 (ja) * 1999-11-02 2010-10-20 塩野義製薬株式会社 着色顆粒の色素定着法
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
MXPA02012793A (es) * 2000-06-23 2004-07-30 Teva Pharmaceuticals Ltd Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion.
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
WO2003097018A1 (en) * 2002-02-04 2003-11-27 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
BR0115585A (pt) 2000-11-28 2005-12-13 Fmc Corp Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
EP1347748A2 (en) * 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatic delivery system for controlled delivery of agent
KR100685945B1 (ko) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 액정표시장치 및 그 제조방법
US8268333B2 (en) * 2001-04-24 2012-09-18 Lintec Corporation Orally administered agent and an orally administered agent/supporting substrate complex
DE10120092B4 (de) * 2001-04-25 2008-03-20 Lts Lohmann Therapie-Systeme Ag Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
IL159812A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
AU2002340470A1 (en) 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US20030135065A1 (en) * 2001-11-13 2003-07-17 Ramy Lidor-Hadas Process for the production of L-DOPA ethyl ester
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
WO2003053450A1 (de) * 2001-12-21 2003-07-03 Biopartners Gmbh Ribavirin-granulat zur herstellung von filmtabletten
KR20030056474A (ko) * 2001-12-28 2003-07-04 한국유나이티드제약 주식회사 카르비도파/레보도파 서방정의 조성물과 그의 제조방법
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US7008979B2 (en) * 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
WO2004026283A1 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US20040091538A1 (en) * 2002-10-31 2004-05-13 Crystal Pollock-Dove Dosage form providing ascending release of liquid formulation
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
WO2005058319A1 (en) 2003-12-16 2005-06-30 Cnsbio Pty Ltd Methods and compositions
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005084703A1 (ja) * 2004-03-09 2005-09-15 Nrl Pharma, Inc. 徐放性の口腔用組成物
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
JP5046946B2 (ja) * 2004-10-15 2012-10-10 スパーナス ファーマシューティカルズ インコーポレイテッド 低乱用性薬学的製剤
KR20130115401A (ko) * 2004-11-19 2013-10-21 글락소스미스클라인 엘엘씨 약제학적 제품
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
AU2006263338A1 (en) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
KR101655455B1 (ko) * 2005-09-09 2016-09-07 안젤리니 라보팜 엘엘씨 일일 1회 투여를 위한 트라조돈 조성물
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007072495A2 (en) * 2005-11-03 2007-06-28 Sun Pharmaceutical Industries Limited Coated tablets having prolonged gastric retention
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions
US7674396B2 (en) * 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
KR100752417B1 (ko) * 2006-02-14 2007-08-28 대원제약주식회사 안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
CN101484165A (zh) * 2006-05-03 2009-07-15 Cns生物有限公司 治疗炎性疼痛的方法与组合物
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US8158156B2 (en) 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US9101544B2 (en) * 2006-08-30 2015-08-11 Jagotec Ag Controlled release nisoldipine compositions
WO2008039186A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
WO2008039193A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
US20080181947A1 (en) * 2006-09-26 2008-07-31 Astellas Pharma Inc. Controlled release dosage form of tacrolimus
EP1935411A1 (en) 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Slow release excipient and its use
EP2063867A2 (en) * 2006-12-22 2009-06-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
AT505225A1 (de) * 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
KR20110025833A (ko) * 2008-06-16 2011-03-11 아피언 랍스, 엘엘씨 활성제의 일정한 (0-차) 방출을 위한 방출 시스템의 조성물 및 제조방법
EP2326310B1 (en) * 2008-08-15 2019-05-15 Assertio Therapeutics, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
CA2739246A1 (en) * 2008-10-08 2010-04-15 Bioplus Life Sciences Pvt. Ltd. Sustained release drug delivery system
US20100112054A1 (en) * 2008-10-23 2010-05-06 Appian Labs, Llc Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
EP2210585A1 (en) 2009-01-16 2010-07-28 Exelgyn SPRM pharmaceutical compositions methods of treatment using them
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
WO2011078993A1 (en) 2009-12-21 2011-06-30 Aptapharma, Inc. Functionally-coated multilayer tablets
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
JP5459670B2 (ja) * 2010-05-07 2014-04-02 塩野義製薬株式会社 着色顆粒の色素定着化剤
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2013213317B2 (en) 2012-01-23 2016-06-30 Sun Pharmaceutical Industries Limited In-situ multilayered tablet technology
US10166207B2 (en) 2013-06-05 2019-01-01 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
AU2014332024B2 (en) 2013-10-07 2019-09-26 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
RU2016151697A (ru) 2014-06-02 2018-07-10 Тева Фармасьютикал Индастриз Лтд. Расправляемая удерживаемая в желудке лекарственная форма
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
WO2016115253A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Ofcolordo, A Body Corporate Insulin mimotopes and methods of using the same
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9820957B2 (en) 2016-03-24 2017-11-21 The Regents Of The University Of Colorado, A Body Corporate Methods of treating autoimmunity
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
ES2966736T3 (es) 2016-12-02 2024-04-24 Clexio Biosciences Ltd Sistema de residencia gástrica
KR102039345B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
JP7433226B2 (ja) 2017-12-01 2024-02-19 ウルトラジェニクス ファーマシューティカル インク． クレアチンプロドラッグ、組成物及びその使用方法
US11547839B2 (en) 2017-12-04 2023-01-10 Clexio Biosciences Ltd. Long acting gastric residence system
JP2021506984A (ja) 2017-12-18 2021-02-22 トリス・フアルマ・インコーポレーテツド トリガーパルス薬物放出を有する胃内滞留型ｒａｆｔ形成システムを含む放出調節薬物粉末組成物
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
IL275312B1 (en) 2017-12-18 2024-05-01 Tris Pharma Inc GHB pharmacy preparations containing a system that creates a floating integrated penetrating polymer network
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
JP2021523882A (ja) * 2018-05-15 2021-09-09 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド 低分子ｅｇｆｒ阻害剤を含む医薬組成物及びその製造方法
CN110214860A (zh) * 2019-07-10 2019-09-10 聂刘明 一种宠物饲料及其制备工艺
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
BR112024001927A2 (pt) * 2021-07-30 2024-04-30 Evecxia Therapeutics Inc Formas de dosagem gastrorretentivas de 5-hidroxitriptofano
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4839171A (en) * 1984-11-30 1989-06-13 Techmix, Inc. Composition for treating impaired lactation
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
JPH0747534B2 (ja) * 1986-06-02 1995-05-24 ロ−ラ−ジヤパン株式会社 錠 剤
US4869908A (en) * 1987-01-09 1989-09-26 K.V. Pharmaceutical Co. Fibre formulations
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time

Also Published As

Publication number Publication date
ATE530173T1 (de) 2011-11-15
ES2376199T3 (es) 2012-03-09
EP0795324A3 (en) 1998-11-04
EP0795324B1 (en) 2004-04-21
ATE264670T1 (de) 2004-05-15
PT795324E (pt) 2004-09-30
DK0795324T3 (da) 2004-08-16
US5780057A (en) 1998-07-14
DE69728710D1 (de) 2004-05-27
CA2197941A1 (en) 1997-08-20
ES2219709T3 (es) 2004-12-01
AU719170B2 (en) 2000-05-04
AU1477697A (en) 1997-08-28
DE69728710T2 (de) 2005-04-07
EP1382331B1 (en) 2011-10-26
EP0795324A2 (en) 1997-09-17
JPH09316005A (ja) 1997-12-09
JP3251190B2 (ja) 2002-01-28
NZ314265A (en) 1997-07-27
ES2376199T8 (es) 2012-04-04
ITMI960311A1 (it) 1997-08-19
EP1382331A1 (en) 2004-01-21
IT1282650B1 (it) 1998-03-31
CA2197941C (en) 2001-12-04

Similar Documents

Publication Publication Date Title
ITMI960311A0 (it)
AR026662A2 (it)
BRPI9713914B8 (it)
IN191992B (it)
IN188590B (it)
ITAN960020A0 (it)
IN191439B (it)
ITCT960008V0 (it)
BR7601346U (it)
BR9603859A (it)
IN187766B (it)
IN182470B (it)
ITMI960438A0 (it)
ITCT960012V0 (it)
BR7600721U (it)
CN3045888S (it)
CN3047919S (it)
CN3041207S (it)
CN3039213S (it)
CN3040367S (it)
CN3045208S (it)
CN3045880S (it)
CN3045853S (it)
CN3045530S (it)
CN3045806S (it)

Legal Events

Date Code Title Description
0001 Granted